-
-
Blood Cancer breakthrough? Jakavi Ruxolitinib Tablets Continues to Show Long-Term Benefit for Patients With Myelofibrosis & Polycythemia Vera.
“JAKAVI” Gets High Marks for Myelofibrosis & Polycythemia Vera Treatment
Before Jakafi, no drug therapies were approved to specifically treat certain types of Myelofibrosis (MF). Instead, Healthcare Professionals used medicines approved for other diseases to try to help control the signs and symptoms of MF.
Jakavi is the first and only prescription medicine approved by the FDA to treat patients with intermediate to high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF and post–essential thrombocythemia MF. This medicine is also indicated for treatment of people with PV who have had an inadequate response to or are intolerant of hydroxyurea.
Jakavi is an oral Janus-associated kinase 1 (JAK1) and JAK2 inhibitor. Overactive JAK signaling is a key contributor to the progression of MF. Jakafi targets JAKs to reduce overactive JAK signaling.
Available Strength :
Jakavi 5mg
Jakavi 15mg and
Jakavi 20mgInterested to know more about Jakavi Benefits and Clinical trials, Go Here – https://bit.ly/2LmDY6n
WHERE TO BUY JAKAVI 5MG, 15mg and 20MG TABLETS?
You can buy Novartis Jakavi at most stores and online pharmacies. Depending on your location, the legality will vary as to how and where you can purchase Jakavi Ruxolitinib tablets, and if you have a prescription, Drugssquare is a good place to start out if you are looking to purchase online.
We do all that we can in meeting our customer’s expectations. Providing medicines of the best quality and serving with a smile. We know that when the customer is in need of our services, he is already under stress, both physical and mental. We make sure, the customer is served with human touch and can trust Drugssquare for providing medicines at a reasonable price in a nice and friendly environment.
-
You must be logged in to post a comment.